Boehringer Ingelheim to announce positive results from its RE-COVER study

[News]

Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.

More... (http://www.news-medical.net/news/20091202/Boehringer-Ingelheim-to-announce-positive-results-from-its-RE-COVER-study.aspx)